Impact of IL‐17A and IL‐23p19 Inhibitors on Psychiatric Outcomes and Inflammation in Psoriasis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 12.10.2026
DOI: 10.1111/ddg.70579 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 12.10.2026. Verfasst von Ilknur Kıvanc Altunay und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Dermatology Department, Istanbul, Turkiye. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives Psoriasis is a systemic inflammatory disease affecting skin and mental health. Biologic agents targeting IL‐17A and IL‐23p19 effectively treat skin symptoms, but their psychiatric and systemic anti‐inflammatory effects remain unclear, especially in real‐life settings. This study evaluated whether IL‐17A and IL‐23p19 inhibitors improve psychiatric symptoms, and whether these improvements are associated with reductions in inflammatory markers, independently of skin response. Patients and Methods In this multicenter prospective study, 235 psoriasis patients starting IL‐17A and IL‐23p19 inhibitors were assessed at baseline and six months. Assessments included CRP, NLR, HADS‐A, HADS‐D, and DLQI scores.
Results
Treatment significantly improved skin, quality of life, and psychiatric scores (p < 0.001). CRP declined significantly and was independently correlated with reductions in HADS‐A and HADS‐D scores, even in patients without PASI90 response. IL‐23p19 inhibitors produced greater reductions in CRP and NLR compared to IL‐17A inhibitors, suggesting broader anti‐inflammatory effects through upstream cytokine blockade.
Conclusions
IL‐17A and IL‐23p19 inhibitors improve both dermatological and psychiatric outcomes in psoriasis, potentially by reducing systemic inflammation. CRP may serve as a biomarker of psychiatric improvement, independent of skin response. Future studies with longer follow‐up and non‐biologic control groups are warranted. Integrating dermatological and psychiatric care may enhance outcomes in psoriasis patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Dermatology Department, Istanbul, Turkiye.
- Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkiye.
- University of Health Sciences, Başakşehir Çam and Sakura City Hospital, Dermatology Department, Istanbul, Türkiye.
- Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Dermatology and Venereology Department, Istanbul, Türkiye.
- Prof. Dr. Cemil Taşcıoğlu City Hospital, Dermatology Department, Istanbul, Türkiye.
ORCID-Profile: Aysenur Demir, Ahmet Kayaalti
Zitieren
APA
Altunay, I. K., Demir, A., Kayaalti, A., Aptoula, S. I., Canat, H. D., Engin, B., Erkoc, Y. C., Topal, I. O., & Kul, A. (2026). Impact of IL‐17A and IL‐23p19 Inhibitors on Psychiatric Outcomes and Inflammation in Psoriasis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70579
Vancouver
Altunay IK, Demir A, Kayaalti A, Aptoula SI, Canat HD, Engin B, et al. Impact of IL‐17A and IL‐23p19 Inhibitors on Psychiatric Outcomes and Inflammation in Psoriasis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70579
BibTeX
@article{Altunay2026,
author = {Altunay, Ilknur Kıvanc and Demir, Aysenur and Kayaalti, Ahmet and Aptoula, Sena Inal and Canat, Harbiye Dilek and Engin, Burhan and Erkoc, Yusuf Can and Topal, Ilteris Oguz and Kul, Aslihan},
title = {Impact of IL‐17A and IL‐23p19 Inhibitors on Psychiatric Outcomes and Inflammation in Psoriasis},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
doi = {10.1111/ddg.70579}
}
EUVIMED